http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106674352-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-78 |
| filingDate | 2015-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106674352-B |
| titleOfInvention | Derivative of antineoplastic protein endostatin and application thereof |
| abstract | The invention discloses a derivative of antitumor protein endostatin, wherein the amino acid sequence of endostatin is shown in SEQ.ID.NO4; characterized in that the derivatives comprise: endostatin is linked to the antibody IgG invariant region; or Arg is introduced in front of the N end of endostatin; or the amino acid short peptide of glycosylation sites is introduced in front of the N end, or behind the C end, or in front of the N end and behind the C end of the endostatin; or one Arg of Arg62Arg63 of the amino acid sequence of endostatin is point mutated, or one Arg of Arg128Arg129 is point mutated, or one Arg of Arg62Arg63 is point mutated while one Arg of Arg128Arg129 is point mutated; the derivative of the antitumor protein endostatin has the advantages of stability in vivo, long half-life period and high antitumor bioactivity. |
| priorityDate | 2015-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.